“No clear explanation why the findings of the SWEDEPAD 2 are given greater methodological weight than extensive body of randomised evidence”

In part two of a Charing Cross (CX) Symposium special roundtable discussion on the use of drug-based technology use in the lower extremity, Peter Schneider (University of California, San Francisco, USA), Sabine Steiner (Vienna, Austria), Mårten Falkenberg (Sahlgrenska University Hospital and the University of Gothenburg, Gothenberg, Sweden) and Koen Deloose (AZ Sint-Blasius Hospital, Dendermonde, Belgium) wrestle with SWEDEPAD 2 and the updated European Society for Vascular Surgery (ESVS) focused update on guidelines for the management of claudication.